Synthesis of deuterium-labeled CCR2 antagonist JNJ-26131300, [4-(1H-indol- 3-yl)-piperidin-1-yl]-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid.

J Labelled Comp Radiopharm

Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.

Published: May 2022

Synthesis of multiple deuterium-labeled CCR2 antagonist JNJ-26131300, that is, [4-(1H-indol-3-yl)-piperidin-1-yl]-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid, is described. First, condensation of indole-D with 4-piperidone produced 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-D , which subsequently underwent catalytic hydrogenation to give 3-piperidin-4-yl-1H-indole-D . Next, bromo-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid was prepared through multiple steps from 3-(3,4,5-trifluoro-phenyl)-acrylic acid and bromo-piperidin-4-yl-acetic acid ethyl ester. Nucleophilic coupling of 3-piperidin-4-yl-1H-indole-D with bromo-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid afforded the desired compound [4-(1H-indol-3-yl)-piperidin-1-yl]-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid-D .

Download full-text PDF

Source
http://dx.doi.org/10.1002/jlcr.3967DOI Listing

Publication Analysis

Top Keywords

deuterium-labeled ccr2
8
ccr2 antagonist
8
antagonist jnj-26131300
8
3-piperidin-4-yl-1h-indole-d bromo-{1-[3-345-trifluoro-phenyl-acryloyl]-piperidin-4-yl}-acetic
8
bromo-{1-[3-345-trifluoro-phenyl-acryloyl]-piperidin-4-yl}-acetic acid
8
acid
6
synthesis deuterium-labeled
4
jnj-26131300 [4-1h-indol-
4
[4-1h-indol- 3-yl-piperidin-1-yl]-{1-[3-345-trifluoro-phenyl-acryloyl]-piperidin-4-yl}-acetic
4
3-yl-piperidin-1-yl]-{1-[3-345-trifluoro-phenyl-acryloyl]-piperidin-4-yl}-acetic acid
4

Similar Publications

Synthesis of deuterium-labeled CCR2 antagonist JNJ-26131300, [4-(1H-indol- 3-yl)-piperidin-1-yl]-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid.

J Labelled Comp Radiopharm

May 2022

Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.

Synthesis of multiple deuterium-labeled CCR2 antagonist JNJ-26131300, that is, [4-(1H-indol-3-yl)-piperidin-1-yl]-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid, is described. First, condensation of indole-D with 4-piperidone produced 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-D , which subsequently underwent catalytic hydrogenation to give 3-piperidin-4-yl-1H-indole-D . Next, bromo-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid was prepared through multiple steps from 3-(3,4,5-trifluoro-phenyl)-acrylic acid and bromo-piperidin-4-yl-acetic acid ethyl ester.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!